0001893645
false
2026-06-30
Q2
--12-31
0001893645
2026-01-01
2026-06-30
0001893645
us-gaap:PrivatePlacementMember
plrz:PIPEOrdinaryWarrantsMember
srt:ScenarioForecastMember
2026-09-04
0001893645
us-gaap:PrivatePlacementMember
plrz:PIPEOrdinaryWarrantsMember
srt:ScenarioForecastMember
2026-09-04
2026-09-04
0001893645
us-gaap:PrivatePlacementMember
plrz:PreFundedWarrantsMember
srt:ScenarioForecastMember
2026-09-04
2026-09-04
0001893645
us-gaap:IPOMember
plrz:PreFundedWarrantsMember
srt:ScenarioForecastMember
2026-09-04
0001893645
us-gaap:IPOMember
us-gaap:CommonStockMember
srt:ScenarioForecastMember
2026-09-04
0001893645
us-gaap:IPOMember
plrz:PreFundedWarrantsMember
srt:ScenarioForecastMember
2026-09-04
2026-09-04
0001893645
us-gaap:IPOMember
us-gaap:CommonStockMember
srt:ScenarioForecastMember
2026-09-04
2026-09-04
0001893645
srt:ScenarioForecastMember
2026-09-04
0001893645
srt:ScenarioForecastMember
2026-09-04
2026-09-04
0001893645
us-gaap:SubsequentEventMember
plrz:QuantumXLabsIncMember
2026-07-02
2026-07-02
0001893645
us-gaap:SubsequentEventMember
plrz:QuantumXLabsIncMember
2026-07-02
0001893645
2025-01-01
2025-06-30
0001893645
plrz:ExchangeWarrantsMember
2025-01-01
2025-06-30
0001893645
plrz:ExchangeWarrantsMember
2026-01-01
2026-06-30
0001893645
plrz:SeriesAWarrantsMember
2025-01-01
2025-06-30
0001893645
plrz:April2026WarrantsMember
2026-01-01
2026-06-30
0001893645
plrz:IPOWarrantsMember
2025-01-01
2025-06-30
0001893645
plrz:IPOWarrantsMember
2026-01-01
2026-06-30
0001893645
plrz:OptionsMember
2025-01-01
2025-06-30
0001893645
plrz:OptionsMember
2026-01-01
2026-06-30
0001893645
us-gaap:ServiceMember
2026-01-01
2026-06-30
0001893645
plrz:GeneralAndAdministrativeExpensesMember
2025-01-01
2025-06-30
0001893645
plrz:GeneralAndAdministrativeExpensesMember
2026-01-01
2026-06-30
0001893645
plrz:ResearchAndDevelopmentExpensesMember
2025-01-01
2025-06-30
0001893645
plrz:ResearchAndDevelopmentExpensesMember
2026-01-01
2026-06-30
0001893645
2026-05-14
2026-05-14
0001893645
srt:ChiefExecutiveOfficerMember
us-gaap:SubsequentEventMember
2026-07-13
2026-07-13
0001893645
us-gaap:RestrictedStockUnitsRSUMember
2026-05-14
2026-05-14
0001893645
plrz:TwoThousandTwentyOnePlanMember
2026-06-30
0001893645
us-gaap:CommonStockMember
2025-11-28
0001893645
2025-11-28
2025-11-28
0001893645
us-gaap:CommonStockMember
2025-11-28
2025-11-28
0001893645
plrz:PIPEOrdinaryWarrantsMember
2026-06-30
0001893645
us-gaap:WarrantMember
2026-04-08
0001893645
plrz:PIPEPrefundedWarrantsMember
2026-04-08
0001893645
plrz:PreFundedWarrantsMember
2026-04-08
2026-04-08
0001893645
us-gaap:CommonStockMember
2026-04-08
2026-04-08
0001893645
us-gaap:PrivatePlacementMember
2026-04-08
2026-04-08
0001893645
plrz:ConsultantsMember
2026-03-31
2026-03-31
0001893645
us-gaap:CommonStockMember
plrz:ConsultantsMember
2026-03-31
2026-03-31
0001893645
us-gaap:RestrictedStockUnitsRSUMember
2026-06-30
0001893645
2025-06-30
0001893645
2024-12-31
0001893645
2026-06-30
0001893645
2025-12-31
0001893645
us-gaap:LicenseMember
2026-06-30
0001893645
plrz:LicenseAgreementMember
2026-06-30
0001893645
us-gaap:WarrantMember
2026-01-01
2026-06-30
0001893645
plrz:PreFundedWarrantsMember
2026-01-01
2026-06-30
0001893645
us-gaap:IPOMember
2026-01-01
2026-06-30
0001893645
plrz:SciSparcMember
us-gaap:CommonStockMember
2026-01-01
2026-06-30
0001893645
plrz:AdditionalJurisdictionClinicalMember
2024-08-13
2024-08-13
0001893645
plrz:EURegulatoryBodyMember
2024-08-13
2024-08-13
0001893645
plrz:FDAMember
2024-08-13
2024-08-13
0001893645
plrz:Phase3ClinicalTrialsMember
2024-08-13
2024-08-13
0001893645
plrz:Phase2bClinicalTrialMember
2024-08-13
2024-08-13
0001893645
plrz:Phase2aClinicalTrialMember
2024-08-13
2024-08-13
0001893645
plrz:Phase1ClinicalTrialMember
2024-08-13
2024-08-13
0001893645
plrz:PreclinicalSafetyTestMember
2024-08-13
2024-08-13
0001893645
2024-08-13
2024-08-13
0001893645
plrz:MeasurementInputFairValueMember
us-gaap:FairValueInputsLevel3Member
2026-06-30
0001893645
us-gaap:MeasurementInputExpectedTermMember
us-gaap:FairValueInputsLevel3Member
2026-06-30
0001893645
us-gaap:MeasurementInputRiskFreeInterestRateMember
us-gaap:FairValueInputsLevel3Member
2026-06-30
0001893645
us-gaap:MeasurementInputPriceVolatilityMember
us-gaap:FairValueInputsLevel3Member
2026-06-30
0001893645
us-gaap:MeasurementInputSharePriceMember
us-gaap:FairValueInputsLevel3Member
2026-06-30
0001893645
plrz:MeasurementInputNumberOfWarrantsMember
us-gaap:FairValueInputsLevel3Member
2026-06-30
0001893645
plrz:QuantumXLabsIncMember
2026-01-01
2026-06-30
0001893645
plrz:QuantumXLabsIncMember
2026-07-02
0001893645
plrz:QuantumXLabsIncMember
2026-03-04
0001893645
plrz:QuantumXLabsIncMember
2025-01-01
2025-12-31
0001893645
plrz:TaurusGoldCorpMember
2026-01-01
2026-06-30
0001893645
plrz:TaurusGoldCorpMember
2026-06-30
0001893645
plrz:TaurusGoldCorpMember
2025-10-24
0001893645
plrz:TaurusGoldCorpMember
2025-10-24
2025-10-24
0001893645
plrz:TaurusGoldCorpMember
us-gaap:CommonStockMember
2025-10-24
2025-10-24
0001893645
plrz:TaurusGoldCorpMember
2025-10-10
2025-10-10
0001893645
plrz:TaurusGoldCorpMember
us-gaap:CommonStockMember
2025-10-10
2025-10-10
0001893645
us-gaap:RetainedEarningsMember
2026-06-30
0001893645
us-gaap:AdditionalPaidInCapitalMember
2026-06-30
0001893645
us-gaap:CommonStockMember
2026-06-30
0001893645
us-gaap:RetainedEarningsMember
2026-01-01
2026-06-30
0001893645
us-gaap:CommonStockMember
2026-01-01
2026-06-30
0001893645
us-gaap:AdditionalPaidInCapitalMember
2026-01-01
2026-06-30
0001893645
us-gaap:RetainedEarningsMember
2025-12-31
0001893645
us-gaap:AdditionalPaidInCapitalMember
2025-12-31
0001893645
us-gaap:CommonStockMember
2025-12-31
0001893645
us-gaap:RetainedEarningsMember
2025-06-30
0001893645
us-gaap:AdditionalPaidInCapitalMember
2025-06-30
0001893645
us-gaap:CommonStockMember
2025-06-30
0001893645
us-gaap:RetainedEarningsMember
2025-01-01
2025-06-30
0001893645
us-gaap:AdditionalPaidInCapitalMember
2025-01-01
2025-06-30
0001893645
us-gaap:CommonStockMember
2025-01-01
2025-06-30
0001893645
us-gaap:RetainedEarningsMember
2024-12-31
0001893645
us-gaap:AdditionalPaidInCapitalMember
2024-12-31
0001893645
us-gaap:CommonStockMember
2024-12-31
0001893645
plrz:SeriesAWarrantsMember
2026-01-01
2026-06-30
0001893645
plrz:April2026WarrantsMember
2025-01-01
2025-06-30
iso4217:USD
xbrli:shares
xbrli:shares
iso4217:USD
xbrli:pure
iso4217:CAD
xbrli:shares
iso4217:CAD
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private
Issuer
Pursuant to Rule 13a-16 or
15d-16
under the Securities Exchange Act of 1934
For the month of September 2026
Commission file number: 001-42375
Polyrizon Ltd.
(Translation of registrant’s name into English)
5 Ha-Tidhar Street
Raanana, 4366507, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
CONTENTS
This Report of Foreign Private Issuer on Form
6-K consists of (i) the Registrant’s Interim Condensed Financial Statements as of June 30, 2026, which is attached hereto as Exhibit
99.1; and (ii) the Registrant’s Management’s Discussion and Analysis of Financial Condition and Results of Operations for
the six months ended June 30, 2026, which is attached hereto as Exhibit 99.2.
Exhibit 99.2, Exhibit 99.3 attached to this Form
6-K are incorporated by reference into the Registrant’s Registration Statements on Form S-8 (File No. 333-284410 and 333-288923)
and Form F-3 (333-291368),
filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent
not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
Polyrizon Ltd. |
| |
|
| Date: September 28, 2026 |
By: |
/s/ Tomer Izraeli |
| |
Name: |
Tomer Izraeli |
| |
Title: |
Chief Executive Officer |